Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 119, Issue 37, Pages -Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2201137119
Keywords
Alzheimer's disease; TNF; neuroinflammation; TNFR2 agonist; 20 mouse model
Categories
Funding
- ZonMw and Alzheimer Nederland [70-73305-98-1132]
Ask authors/readers for more resources
This study investigated the effects of stimulating TNFR2 with a TNFR2 agonist (NewStar2) in an AD mouse model. The results demonstrated that activation of TNFR2 reduced amyloid beta deposition and expression of beta-secretase 1, increased microglial and astrocytic activation, promoted the uptake and degradation of A beta, and improved cognitive functions. These findings suggest that TNFR2 stimulation might be a potential treatment for AD.
Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic, proinflammatory cytokine related to different neurodegenerative diseases, including Alzheimer's disease (AD). Although the linkage between increased TNF-alpha levels and AD is widely recognized, TNF-alpha-neutralizing therapies have failed to treat AD. Previous research has associated this with the antithetic functions of the two TNF receptors, TNF receptor 1, associated with inflammation and apoptosis, and TNF receptor 2 (TNFR2), associated with neuroprotection. In our study, we investigated the effects of specifically stimulating TNFR2 with a TNFR2 agonist (NewStar2) in a transgenic A beta-overexpressing mouse model of AD by administering NewStar2 in two different ways: centrally, via implantation of osmotic pumps, or systemically by intraperitoneal injections. We found that both centrally and systemically administered NewStar2 resulted in a drastic reduction in amyloid beta deposition and beta-secretase 1 expression levels. Moreover, activation of TNFR2 increased microglial and astrocytic activation and promoted the uptake and degradation of A beta. Finally, cognitive functions were also improved after NewStar2 treatment. Our results demonstrate that activation of TNFR2 mitigates A beta-induced cognitive deficits and neuropathology in an AD mouse model and indicates that TNFR2 stimulation might be a potential treatment for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available